sigA

primary sigma factor of RNA polymerase

Validation StatusCandidate

Overview

Validation Method: mutant isolation and sequencing, phage transduction, in vitro transcription assay
Drug Classes: Vancomycin|Fosfomycin, Spectinomycin|Tetracycline|Clarithromycin
Organisms: Staphylococcus aureus, Bacillus subtilis, Mycobacterium smegmatis
Papers: 3
Databases: Reslit
Mutations: 2

Mutations

Protein Change	Nucleotide Change	Mechanism	Organism	Resistance To	Database	Validation Status
G336C	-	reduces susceptibility to vancomycin and fosfomycin by altering promoter recognition.	Bacillus subtilis	Vancomycin\|Fosfomycin	Reslit	Candidate
R515H	-	disrupting, knocking out, or mutating the gene causes SUSCEPTIBILITY	Mycobacterium smegmatis	Spectinomycin\|Tetracycline\|Clarithromycin	Reslit	Candidate

Papers3

A Novel Spiro-Heterocyclic Compound Identified by the Silkworm Infection Model Inhibits Transcription in Staphylococcus aureus.

PMID 28487682 · 2017

GPI0363 was identified as a novel anti-staphylococcal agent that targets RNA polymerase. Resistance to GPI0363 was associated with a mutation in the sigA gene, which encodes the primary sigma factor of S. aureus.

Gene Information

Gene Name: sigA
Allele: sigA
Encodes: primary sigma factor of RNA polymerase
Source Database: Reslit
Organisms Tested In: • Staphylococcus aureus
Validation Method: mutant isolation and sequencing, phage transduction, in vitro transcription assay

Browse AMR Genes

sigA

Mutations

Gene Information